Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.
Hidenori Sakai; Koshiro Sonomoto; Shingo Nakayamada; Masanobu Ueno; Atsushi Nagayasu; Takafumi Aritomi; Hiroaki Tanaka; Satoshi Kubo; Ippei Miyagawa; Yasuyuki Todoroki; Yurie Satoh-Kanda; Yuya Fujita; Ryuichiro Kanda; Yoshiya Tanaka
RMD open, Feb. 2026

Association of exercise-induced pulmonary hypertension with nailfold capillary density in systemic sclerosis: a single-center retrospective observational study.
Katsuhide Kusaka; Satoshi Kubo; Shingo Nakayamada; Ippei Miyagawa; Yusuke Miyazaki; Yurie Kanda; Yasuyuki Todoroki; Masanobu Ueno; Ryuichiro Kanda; Koshi Setoyama; Masaharu Kataoka; Yoshiya Tanaka
Arthritis research & therapy, Aug. 2025

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Ryuichiro Kanda; Yusuke Miyazaki; Shingo Nakayamada; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yurie Satoh-Kanda; Naoaki Ohkubo; Yasuyuki Todoroki; Hiroaki Tanaka; Masanobu Ueno; Atsushi Nagayasu; Yuya Fujita; Takafumi Aritomi; Katsuhide Kusaka; Hidenori Sakai; Satsuki Matsunaga; Hirotsugu Nohara; Yoshiya Tanaka
Rheumatology and therapy, Apr. 2025

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus.
Masanobu Ueno; Shigeru Iwata; Kaoru Yamagata; Yasuyuki Todoroki; Koshiro Sonomoto; Atsushi Nagayasu; Ippei Miyagawa; Satoshi Kubo; Yusuke Miyazaki; Hiroko Miyata; Ryuichiro Kanda; Takafumi Aritomi; Shingo Nakayamada; Yoshiya Tanaka
RMD open, Dec. 2024

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Koshiro Sonomoto; Shingo Nakayamada; Yoshihisa Fujino; Hiroko Miyata; Satoshi Kubo; Yuya Fujita; Yoshino Inoue; Satsuki Matsunaga; Shigeru Iwata; Kentaro Hanami; Yasuyuki Todoroki; Hiroko Yoshinari-Korekoda; Akio Kawabe; Ayako Yamaguchi; Masanobu Ueno; Yurie Satoh-Kanda; Ryuichiro Kanda; Masashi Funada; Naoaki Ohkubo; Katsuhide Kusaka; Shumpei Kosaka; Atsushi Nagayasu; Shunsuke Fukuyo; Masao Nawata; Yusuke Miyazaki; Mikiko Tokunaga; Kenichi Tanaka; Yosuke Okada; Yoshiya Tanaka
Rheumatology (Oxford, England), Aug. 2024

Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus.
Yurie Satoh-Kanda; Shingo Nakayamada; Satoshi Kubo; Kaoru Yamagata; Aya Nawata; Hiroaki Tanaka; Shunpei Kosaka; Ryuichiro Kanda; Shan Yu; Yuya Fujita; Koshiro Sonomoto; Yoshiya Tanaka
RMD open, Jun. 2024

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry.
Satoshi Kubo; Yusuke Miyazaki; Yasuyuki Todoroki; Atsushi Nagayasu; Ryuichiro Kanda; Takafumi Aritomi; Satsuki Matsunaga; Masanobu Ueno; Ippei Miyagawa; Koshiro Sonomoto; Kentaro Hanami; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and therapy, Dec. 2023

TGF-β3 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus.
Yu Shan; Shingo Nakayamada; Aya Nawata; Kaoru Yamagata; Koshiro Sonomoto; Hiroaki Tanaka; Yurie Satoh-Kanda; Mai-Phuong Nguyen; Yasuyuki Todoroki; Atsushi Nagayasu; Masanobu Ueno; Ryuichiro Kanda; Yuya Fujita; Tong Zhang; He Hao; Jieqing Zhou; Xiaoxue Ma; Junpei Anan; Anh Phuong Nguyen; Yoshiya Tanaka
Rheumatology (Oxford, England), Jul. 2023

Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.
Yasuyuki Todoroki; Satoshi Kubo; Kazuhisa Nakano; Yusuke Miyazaki; Masanobu Ueno; Yurie Satoh-Kanda; Ryuichiro Kanda; Ippei Miyagawa; Kentaro Hanami; Keisuke Nakatsuka; Kazuyoshi Saito; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology (Oxford, England), Nov. 2022

An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus.
Maiko Hajime Sumikawa; Shigeru Iwata; Mingzeng Zhang; Hiroko Miyata; Masanobu Ueno; Yasuyuki Todoroki; Atsushi Nagayasu; Ryuichiro Kanda; Koshiro Sonomoto; Keiichi Torimoto; Seunghyun Lee; Shingo Nakayamada; Kazuo Yamamoto; Yosuke Okada; Yoshiya Tanaka
Rheumatology (Oxford, England), Jul. 2022

mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors.
Mingzeng Zhang; Shigeru Iwata; Koshiro Sonomoto; Masanobu Ueno; Yuya Fujita; Junpei Anan; Yusuke Miyazaki; Naoaki Ohkubo; Maiko Hajime Sumikawa; Yasuyuki Todoroki; Hiroko Miyata; Atsushi Nagayasu; Ryuichiro Kanda; He Hao; Gulzhan Trimova; Seunghyun Lee; Shingo Nakayamada; Kei Sakata; Yoshiya Tanaka
Rheumatology (Oxford, England), Jul. 2022

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease.
Satoshi Kubo; Ryuichiro Kanda; Aya Nawata; Yusuke Miyazaki; Akio Kawabe; Kentaro Hanami; Keisuke Nakatsuka; Kazuyoshi Saito; Shingo Nakayamada; Yoshiya Tanaka
RMD open, Mar. 2022

Remission of Granulomatosis with Polyangiitis Only After Resection of a Pulmonary Nodule.
Ryuichiro Kanda; Kazuhisa Nakano; Aya Nawata; Shigeru Iwata; Shingo Nakayamada; Yoshiya Tanaka
Internal medicine (Tokyo, Japan), 2022

Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis.
Shigeru Iwata; Mingzeng Zhang; Maiko Hajime; Naoaki Ohkubo; Koshiro Sonomoto; Keiichi Torimoto; Yukihiro Kitanaga; Gulzhan Trimova; Yasuyuki Todoroki; Hiroko Miyata; Masanobu Ueno; Atsushi Nagayasu; Ryuichiro Kanda; Kazuhisa Nakano; Shingo Nakayamada; Kei Sakata; Yoshiya Tanaka
Rheumatology (Oxford, England), Nov. 2021

A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease.
Ryuichiro Kanda; Satoshi Kubo; Kazuhisa Nakano; Akio Kawabe; Aya Nawata; Kentaro Hanami; Shingo Nakayamada; Yoshiya Tanaka
Modern rheumatology case reports, Jul. 2020

A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor-α (TNF-α) inhibitor, adalimumab.
Ryuichiro Kanda; Kazuhisa Nakano; Ippei Miyagawa; Shigeru Iwata; Shingo Nakayamada; Yoshiya Tanaka
Modern rheumatology case reports, Jul. 2020